Clinical Trial Update: Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial comparing ipilimumab to pemetrexed in non-squamous non-small cell lung cancer was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• Pemetrexed (Alimta) (pemetrexed)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lung Cancer - Non Small Cell | Phase 2 | Status: TERMINATED | Results posted: 2014-05-12